Novel synthesis and biological evaluation of enigmols as therapeutic agents for treating prostate cancer

ACS Medicinal Chemistry Letters

Volumn 2, Issue 6, 2011, Pages 438-443

  Garnier Amblard, Ethel C ^a   Mays, Suzanne G ^b   Arrendale, Richard F ^a   Baillie, Mark T ^a   Bushnev, Anatoliy S ^a   Culver, Deborah G ^a   Evers, Taylor J ^a   Holt, Jason J ^a   Howard, Randy B ^a   Liebeskind, Lanny S ^a   Menaldino, David S ^a   Natchus, Michael G ^a   Petros, John A ^b,c   Ramaraju, Harsha ^b   Reddy, G Prabhakar ^a   Liotta, Dennis C ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

1 deoxysphingoid bases; Enigmol; Liebeskind Srogl reaction; LNCaP; palladium cross coupling; PC 3; prostate cancer therapy

Indexed keywords

ALANINE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DOCETAXEL; ENIGMOL; N METHYLENIGMOL; SPHINGOLIPID; THIOESTER; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; CROSS COUPLING REACTION; DIASTEREOISOMER; DISTRIBUTION VOLUME; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENANTIOSELECTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; METHYLATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

MUS MUSCULUS;

EID: 79959226770     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml2000164     Document Type: Article

References (35)

1. American Cancer Society (ACS). Cancer Facts and Figures, 2010 (Accessed July 2, (2010, at http://www.cancer.org/).
2. Miyamoto, H.; Messing, E.; Chang, C. Androgen deprivation therapy for prostate cancer: current status and future prospects The Prostate 2004, 9999:1, 1-22
3. Berthold, D. R.; Pond, G. R.; Soban, F.; de Wit, R.; Eisenberger, M.; Tannock, I. F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 27 study J. Clin. Oncol. 2008, 26, 242-245
4. Liao, J.; Tao, J.; Lin, G.; Liu, D. Chemistry and biology of sphingolipids Tetrahedron 2005, 61, 4715-4733 (Pubitemid 40591599)
5. Zheng, W.; Kollmeyer, J.; Symolon, H.; Momin, A.; Munter, E.; Wang, E.; Kelly, S.; Allegood, J.; Liu, Y.; Peng, Q.; Ramaraju, H.; Sullards, M.; Cabot, M.; Merrill, A. H., Jr. Ceramides and other bioactive sphingolipid backbones in health and disease: Lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling, and autophagy Biochim. Biophys. Acta 2006, 1758, 1864-1884 (Pubitemid 44879367)
6. Morales, A.; Fernandez-Checa, J. Pharmacological modulation of sphingolipids and role in disease and cancer cell biology Mini-Rev. Med. Chem. 2007, 7, 371-382 (Pubitemid 46681760)
7. Nussbaumer, P. Medicinal chemistry aspects of drug targets in sphingolipid metabolism ChemMedChem 2008, 3, 543-551
8. For references that describe the link between S1P and cancer, see refs 8-12: Payne, S. G.; Milstien, S.; Spiegel, S. Sphingosine-1-phosphate: dual messenger functions FEBS Lett. 2002, 531, 54-57 (Pubitemid 35232784)
9. Spiegel, S.; Milstien, S. Sphingosine-1-phosphate: an enigmatic signaling lipid Nat. Rev. Mol. Cell Biol. 2003, 4, 397-407
10. Sabbadini, R. A. Targeting sphingosine-1-phosphate for cancer therapy Br. J. Cancer 2006, 95, 1131-1135 (Pubitemid 44658473)
11. Pyne, N. J.; Pyne, S. Sphingosine-1-phosphate and cancer Nat. Rev. Cancer 2010, 10, 489-503
12. Leong, W. I.; Saba, J. D. S1P Metabolism in cancer and other pathological conditions Biochimie 2010, 92, 716-723
13. Merrill, A. H., Jr.; Nimkar, S.; Menaldino, D.; Hannun, Y. A.; Loomis, C.; Bell, R. M.; Tyagi, S. R.; Lambeth, J. D.; Stevens, V. L.; Hunter, R.; Liotta, D. C. Structural requirements for long chain (sphingoid) base inhibition of protein kinase C in vitro and for the cellular effects of these compounds Biochemistry 1989, 28, 3138-3145 (Pubitemid 19121904)
14. Humph, H. U.; Schmelz, E. M.; Meredith, F. I. Acylation of naturally occurring and synthetic 1-deoxysphinganines by ceramide synthase J. Biol. Chem. 1998, 273, 19060-19064
15. Symolon, H.; Bushnev, A.; Peng, Q.; Ramaraju, H.; Mays, S. G.; Allegood, J. C.; Pruett, S. T.; Sullards, M. C.; Dillehay, D. L.; Liotta, D. C.; Merrill, A. H., Jr. Enigmol: A novel sphingolipid analog with anti-cancer activity against cancer cell lines and in in vivo models for intestinal and prostate cancer. Mol. Cancer Ther. 2010, in press.
16. Pruett, S. T. Biological mass spectrometry of sphingolipids in drug discovery and development chemistry. Ph.D. Thesis, Emory University, Atlanta, GA, 2006; p 169.
17. Previously described syntheses of enigmol are described in refs 17 - 19: Bushnev, A. S.; Baillie, M. T.; Holt, J. J.; Menaldino, D. S.; Merrill, A. H., Jr.; Liotta, D. C. An efficient asymmetric synthesis of Enigmols (1-deoxy-5-hydroxysphingoid bases), an important class of bioactive lipid modulators ARKIVOC 2010, 8, 263-277
18. Wiseman, J. M.; McDonald, F. E.; Liotta, D. C. 1-Deoxy-5- hydroxysphingolipids as new anticancer principles: an efficient procedure for stereoselective syntheses of 2-amino-3,5-diols. Org. Lett. 2005, 7, 3155 - 3157 (Addition and correction: Wiseman, J. M.; McDonald, F. E.; Liotta, D. C. Org. Lett. 2007, 9, 2959).
19. Menaldino, D. S. Asymmetric Syntheses of Amino Alcohols as Bioactive Compounds. Chapter One: Syntheses of Sphingolipid Analogs as Inhibitors of the Protein Kinase C Enzyme System. Chapter Two: Syntheses of Fumonisin Analogs as Non-Metabolizable Protein Kinase C Inhibitors and as Proposed Ceramide Synthase Inhibitors. Ph.D. Thesis, Emory University, Atlanta, GA, 1992.
20. Yang, H.; Liebeskind, L. S. A concise and scalable synthesis of high enantiopurity (-)- d-erythro -sphingosine using peptidyl thiol ester-boronic acid cross-coupling Org. Lett. 2007, 9, 2993-2995
21. Liebeskind, L. S.; Yang, H. Synthesis of sphingosines and their derivatives. PCT Int. Appl. (2008), WO CAN 148:331478 AN 2008:317747.
22. On a large scale, thiol ester 1 was prepared in 99% yield and 99.6% ee, using reagent supported on resin. PS-Carbodiimide and PS-thiophenol are both commercially available from Biotage.
23. Liebeskind, L. S.; Srogl, J. Thiol ester-boronic acid coupling. A mechanistically unprecedented and general ketone synthesis J. Am. Chem. Soc. 2000, 122, 11260-11261
24. Using THF, as previously described for the synthesis of Sphingosine led to moderate yields and significant homocoupling product.
25. Hoffmann, R. V.; Maslouh, N.; Cervantes-Lee, F. Highly stereoselective syntheses of syn- and anti-1,2-amino alcohols J. Org. Chem. 2002, 67, 1045-1056 (Pubitemid 34178185)
26. Shang, S.; Idaware, H.; Macks, D. E.; Ambrosini, L. M.; Tan, D. S. A unified synthetic approach to polyketides having both skeletal and stereochemical diversity Org. Lett. 2007, 9, 1895-1898
27. 2, or oxone reaction conditions led to either low reactivity or moderate diastereoselectivity.
28. Benedetti, F.; Berti, F.; Norbedo, S. Epoxyalcohol route to hydroxyethylene dipeptide isosteres. Stereodivergent synthesis of the diamino alcohol core of ritonavir and its C-2 epimer J. Org. Chem. 2002, 67, 8635-8643 (Pubitemid 35403018)
29. 13C NMR analysis. Final compounds 5a - 5d were also compared with authentic samples, kindly provided by Dr. Anatoliy Bushnev. See Supporting Information for more details.
30. Liu, C.; Cripe, T. P.; Kim, M. O. Statistical Issues in Longitudinal Data Analysis for Treatment Efficacy Studies in the Biomedical Sciences Mol. Ther. 2010, 18, 1724-1730
31. Rayburn, E. R.; Wang, W.; Zhang, Z.; Li, M.; Zhang, R.; Wang, H. Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy Prostate 2006, 66, 1653-1663 (Pubitemid 44646356)
32. In vivo data for the SRR diastereomer (5d) was not included because of stability issues associated with this compound. Significant decomposition was observed for this diastereomer when performing a postassay LCMS analysis of the study samples. Further studies regarding compound stability and in vivo efficacy are ongoing.
33. Liu, L.; Coker, A. L.; Du, X. L.; Cormier, J. N.; Ford, C. E.; Fang, S. Long-term survival after radical prostatectomy compared to other treatments in older men with local/regional prostate cancer J. Surg. Oncol. 2008, 97, 583-591 (Pubitemid 351794147)
34. Azaka, H.; Hinotsu, S.; Usami, M.; Arai, Y.; Kanetake, H.; Naito, S.; Hirao, Y. Combined androgen blockade with bicalutamide for advanced prostate cancer Cancer 2009, 115, 3437-3445
35. Wright, J. L.; Higano, C. S.; Lin, D. W. Intermittent androgen deprivation: Clinical experience and practical applications Urol. Clin. N. Am. 2006, 33, 167-179